News Filter by: Industry Team Airport & AviationAutomotiveEnergyFood & Beverage Health CareHospitality & LeisureInsurance & ReinsuranceLife Sciences ManufacturingSportsTechnology Practice Area Corporate All CorporateEmployee Benefits & Executive CompensationEnvironmentalEstates & TrustsFinance Private Equity & Venture CapitalReal EstateSecurities, Commodities & Exchange RegulationTaxationTransactions Government Solutions All Government SolutionsExport Controls & National SecurityFDA RegulatoryFederal & State Energy RegulatoryFreight & Commuter RailGovernment Procurement Immigration, Nationality & Consular LawNHTSA & Motor Vehicle SafetyPolitical LawPublic PolicyStrategic Communications Intellectual Property All Intellectual PropertyBusiness Method & Software PatentsChemical, Biotechnology & PharmaceuticalCybersecurityElectronicsGreen Energy TechnologiesIP Asset Management IP Due DiligenceIP LitigationMechanical & Electromechanical TechnologiesPatent Office TrialsTechnology Transactions & OutsourcingTrademark, Copyright & Advertising Counseling International All InternationalChinaEurope IsraelJapanMexico Litigation All LitigationAntitrustAppellateBankruptcy & Business ReorganizationsBusiness Litigation & Dispute ResolutionConstructionConsumer Law, Finance & Class Action Distribution & FranchiseGovernment Enforcement Defense & InvestigationsInsurance & Reinsurance LitigationLabor & EmploymentPrivacy, Security & Information ManagementSecurities Enforcement & LitigationTrade Secret Noncompete Litigation Office AustinBostonChicagoDallasDetroitJacksonvilleLos Angeles MadisonMexico CityMiamiMilwaukeeNew YorkOrlandoSacramento San DiegoSan FranciscoSilicon ValleyTallahasseeTampaTokyoWashington, D.C. Topic Big DataCuba Foreign Corrupt Practices Act (FCPA)Health Care Reform Telemedicine In the News Press Releases Media Contact Jill Chanen Public Relations Manager jchanen foley.com 312.832.4745 123next 15 May 2018 Rosen Comments on Proposed Changes in FDA Drug-Device Rules –Bloomberg Law Partner David Rosen is quoted in a Bloomberg Law article, “Drug-Device Rules Could Give FDA Leg Up in Industry Fights,” about the FDA’s plan to revamp its rules on how to deal with overlapping drug, device and biologic products. 05 April 2018 Beaver Addresses Effect of New DOJ Policy on FDA Enforcement Actions –Food Quality & Safety Partner Nate Beaver was quoted in an article for Food Quality & Safety, “What DOJ’s Policy on FDA Guidance Really Means,” about the impact that a new Justice Department policy prohibiting government litigators in civil cases from using noncompliance with guidance documents to prove violations of federal law will have on FDA enforcement actions. 31 January 2018 Rosen Comments on Benefits of More FDA-Approved Generic Drugs –Health Care on Bloomberg Law Partner David Rosen was quoted in a Health Care on Bloomberg Law article, “Critics Say Trump’s Drug Price Talk Empty without Actions.” 18 January 2018 Rosen Quoted in Pink Sheet about New FDA Clinical Study Disclosure Program –Pink Sheet Partner David Rosen was quoted in a Pink Sheet article, “Clinical Study Disclosures Will Make Drug Reviews More Efficient- Gottlieb,” about the implications of a new FDA program linking drug approval documents to sponsors’ clinical study reports. 09 January 2018 Rosen Discusses Clinical Trial Consent Documents in Q&A –Clinical Leader Partner David Rosen was featured in a Clinical Leader Q&A, “Clinical Trial Deaths — Will Clearer Informed Consent Documents Be Enough?” 29 December 2017 Beaver Addresses FDA’s Planned New Guidance for Drug Developers –BNA Health Care Blog Partner Nathan Beaver was quoted in a BNA Health Care Blog article, ”FDA to Provide Earlier, Better Advice to Drug Developers,” about the FDA’s efforts to enhance its communications with drug suppliers as a way of lowering the cost of drug development. 05 December 2017 Rosen Comments on Proposed New FDA Guidance on Drug-Device Combination Products –Health Care on Bloomberg Law Partner David Rosen is quoted in a Health Care on Bloomberg Law article, “FDA Seeks to Speed Approvals of Generic Drug-Device Combos,” about proposed new FDA guidance that will make it easier for generic companies to get drug-device combination products approved. 28 November 2017 Rosen Comments on FDA Commissioner’s Remarks –Pink Sheet Partner David Rosen is quoted in a Pink Sheet article, “Gottlieb’s Complex Generics Remarks Could Signal (Some) Increased Flexibility,” about FDA Commissioner Scott Gottlieb’s remarks on generic copies of products with drug and device constituent parts at an internal FDA event for agency scientists and researchers. 15 November 2017 Foley Survey Shows Surging Telemedicine Services Across the Health Care Spectrum, into Foreign Markets Foley’s 2017 Telemedicine and Digital Health Survey reflects a surging demand for telemedicine-based offerings among providers and patients, and a broader acceptance of the technology by other major players in the health care industry. 15 August 2017 Foley Attorneys Recognized in The Best Lawyers in America 2018 List –Best Lawyers Foley announced today that 25 attorneys earned Best Lawyers® 2018 “Lawyer of the Year” recognition in their respective practice areas, receiving the top nod from Best Lawyers. 123next Search News Filters applied: Search phrase entered: Sort results by: Most Recent Most Viewed Most Shared
15 May 2018 Rosen Comments on Proposed Changes in FDA Drug-Device Rules –Bloomberg Law Partner David Rosen is quoted in a Bloomberg Law article, “Drug-Device Rules Could Give FDA Leg Up in Industry Fights,” about the FDA’s plan to revamp its rules on how to deal with overlapping drug, device and biologic products.
05 April 2018 Beaver Addresses Effect of New DOJ Policy on FDA Enforcement Actions –Food Quality & Safety Partner Nate Beaver was quoted in an article for Food Quality & Safety, “What DOJ’s Policy on FDA Guidance Really Means,” about the impact that a new Justice Department policy prohibiting government litigators in civil cases from using noncompliance with guidance documents to prove violations of federal law will have on FDA enforcement actions.
31 January 2018 Rosen Comments on Benefits of More FDA-Approved Generic Drugs –Health Care on Bloomberg Law Partner David Rosen was quoted in a Health Care on Bloomberg Law article, “Critics Say Trump’s Drug Price Talk Empty without Actions.”
18 January 2018 Rosen Quoted in Pink Sheet about New FDA Clinical Study Disclosure Program –Pink Sheet Partner David Rosen was quoted in a Pink Sheet article, “Clinical Study Disclosures Will Make Drug Reviews More Efficient- Gottlieb,” about the implications of a new FDA program linking drug approval documents to sponsors’ clinical study reports.
09 January 2018 Rosen Discusses Clinical Trial Consent Documents in Q&A –Clinical Leader Partner David Rosen was featured in a Clinical Leader Q&A, “Clinical Trial Deaths — Will Clearer Informed Consent Documents Be Enough?”
29 December 2017 Beaver Addresses FDA’s Planned New Guidance for Drug Developers –BNA Health Care Blog Partner Nathan Beaver was quoted in a BNA Health Care Blog article, ”FDA to Provide Earlier, Better Advice to Drug Developers,” about the FDA’s efforts to enhance its communications with drug suppliers as a way of lowering the cost of drug development.
05 December 2017 Rosen Comments on Proposed New FDA Guidance on Drug-Device Combination Products –Health Care on Bloomberg Law Partner David Rosen is quoted in a Health Care on Bloomberg Law article, “FDA Seeks to Speed Approvals of Generic Drug-Device Combos,” about proposed new FDA guidance that will make it easier for generic companies to get drug-device combination products approved.
28 November 2017 Rosen Comments on FDA Commissioner’s Remarks –Pink Sheet Partner David Rosen is quoted in a Pink Sheet article, “Gottlieb’s Complex Generics Remarks Could Signal (Some) Increased Flexibility,” about FDA Commissioner Scott Gottlieb’s remarks on generic copies of products with drug and device constituent parts at an internal FDA event for agency scientists and researchers.
15 November 2017 Foley Survey Shows Surging Telemedicine Services Across the Health Care Spectrum, into Foreign Markets Foley’s 2017 Telemedicine and Digital Health Survey reflects a surging demand for telemedicine-based offerings among providers and patients, and a broader acceptance of the technology by other major players in the health care industry.
15 August 2017 Foley Attorneys Recognized in The Best Lawyers in America 2018 List –Best Lawyers Foley announced today that 25 attorneys earned Best Lawyers® 2018 “Lawyer of the Year” recognition in their respective practice areas, receiving the top nod from Best Lawyers.